Induction of Adult-like Antibody, Th1, and CTL Responses to Measles Hemagglutinin by Early Life Murine Immunization with An Attenuated Vaccinia-Derived NYVAC(K1L) Viral Vector

Autor: Xavier Martinez, Jiri Kovarik, Muriel Gaillard, Claire-Anne Siegrist, T. Fabian Wild, Paul-Henri Lambert, Paola Bozzotti
Rok vydání: 2001
Předmět:
Male
Time Factors
ddc:616.07
Antibodies
Viral
Th1
chemistry.chemical_compound
Mice
Hemagglutinins
Viral/immunology
Antibodies
Viral/analysis
Mice
Inbred BALB C
ddc:618
Vaccinia virus/genetics
Immunogenicity
Vaccines
Attenuated/administration & dosage
Specific Pathogen-Free Organisms
Female
Measles Vaccine/administration & dosage
Genetic Vectors
Measles Vaccine
Immunization
Secondary
Hemagglutinins
Viral
Vaccinia virus
Biology
Vaccines
Attenuated
Measles
DNA vaccination
Viral vector
Antigen
Virology
medicine
Animals
Humans
measles
Th1 Cells/immunology
murine
vaccinia vector
Measles/immunology/prevention & control
Th1 Cells
T-Lymphocytes
Cytotoxic/immunology
medicine.disease
vaccination
neonates
CTL
Disease Models
Animal
Morbillivirus/immunology
chemistry
Immunization
Animals
Newborn
Morbillivirus
Immunology
Vaccinia
T-Lymphocytes
Cytotoxic
Zdroj: Virology, Vol. 285, No 1 (2001) pp. 12-20
ISSN: 0042-6822
DOI: 10.1006/viro.2001.0945
Popis: Although initially developed in adult animals, novel viral vectors expressing recombinant measles antigens must eventually prove their success in the early life setting, where the efficacy of the currently used live-attenuated measles virus vaccine is limited. The immunological requirements for vaccine candidates include the generation of protective antibody responses as well as the induction of Th1 and cytotoxic T lymphocytes (CTL) responses, which is challenging in the neonatal setting. Here, we report that young BALB/c mice immunized with a single dose of a vaccinia-based NYVAC(K1L) vector generate adult-like antihemagglutinin (HA) antibody responses as well as adult-like Th1 and CTL responses. Despite this strong immunogenicity in early life, antibody responses (but not T-cell responses) to a single dose of NYVAC(K1L)-HA remained susceptible to inhibition by preexisting measles antibodies, calling for use of prime-boost strategies. NYVAC(K1L)-HA is the first attenuated live viral vector demonstrated as capable of inducing adult-like antibody, Th1, and CTL responses against measles in an early life murine immunization model, a capacity previously only reported for measles DNA vaccines.
Databáze: OpenAIRE
Externí odkaz: